Rossari Biotech Limited announced the outcome of its Board Meeting held on January 17, 2026. The Board approved the unaudited financial results for the quarter and nine months ended December 31, 2025, for both standalone and consolidated statements.

In a significant strategic move, the Board granted in-principle approval for the establishment of greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA) by its wholly-owned subsidiary, Rossari International Limited Company. This project aims to enhance supply capabilities, accelerate market entry, and strengthen the company's position in the specialty chemicals sector. Funding for the project will be secured through equity, debt, internal accruals, or a combination thereof.

The Board also approved the allotment of 2,000 equity shares under the Rossari Employee Stock Option Plan - 2019. Following this allotment, the company's issued and paid-up equity share capital increased to ₹11,07,66,732, comprising 55,383,366 equity shares of ₹2 each.

Additionally, the company approved the sale of its office premises located in Kanjurmarg, Mumbai, for a consideration of ₹25 Crores (plus applicable transfer charges). The sale, expected to be completed by March 31, 2026, will not impact business operations and is not considered a sale of undertaking. The buyer is Bhagwati Grand Celebration LLP and is not a related party.

Finally, the Board approved the closure of its wholly-owned subsidiary, Rossari Bangladesh Limited, subject to regulatory approvals. This closure is not expected to have any impact on the company's operations.